Nuwellis (NASDAQ: NUWE) has announced that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance (NoA) for a new patent covering its novel dual-lumen midline catheter technology designed for use in ultrafiltration therapies.
According to Nuwellis, the technology includes separate withdrawal and infusion lumens with pressure-balancing features that help maintain stable flow and reduce complications associated with fluid removal procedures.
In a statement, David Lerner, CTO of Nuwellis, commented, “The allowed patent, ‘Dual Lumen Catheter,’ reflects Nuwellis’ continued investment in innovation to improve fluid management solutions and expand the clinical utility of our Aquadex SmartFlow system. Our team has focused on solving real-world clinical challenges in ultrafiltration therapy, and this technology reflects our commitment to improving both patient outcomes and clinician experience through thoughtful design and engineering.”
